Strong results announced for new LRRK2 inhibitor clinical trial for Parkinson’s

News

Author: Parkinson's Life editorsPublished: 10 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Conceptual illustration of neuron cells with glowing link knots. Synapse and Neuron cells sending electrical chemical signals. Neuron of Interconnected neurons with electrical pulses, 3D rendering

The pharmaceutical company Denali Therapeutics has announced strong positive results from the first in-human LRRK2 inhibitor clinical trial.

The treatment lowers LRRK2 protein activity in body cells, which could ultimately have the potential to slow – or stop – Parkinson’s progression.

The small molecule inhibitor of LRRK2, called DNL201, achieved an average of more than 90% inhibition of LRRK2 kinase activity observed at peak.

Dr Ryan Watts, PhD, CEO of Denali Therapeutics, said: “Mutations in LRRK2 are a major risk factor for Parkinson’s disease. Targeting this degenogene represents a promising approach to develop disease modifying medicines for patients suffering from this terrible disease.”

He continued: “By restoring LRRK2 activity to normal levels, we believe we can reverse lysosomal dysfunction, which could potentially benefit both patients with LRRK2 mutations, as well as idiopathic Parkinson’s disease patients who exhibit lysosomal dysfunction.”

Go Back

Share this story

Comments


  • Wally_McOlly

    Useless news without sharing of the data!

  • Ann Perkins

    Great info – will share it on my FB in US “Parkinsons Hampton Roads”

Related articles


Health & Fitness

Sexuality and Parkinson’s: the needs of caregivers

Tips for maintaining couple intimacy in Parkinson’s

READ MORE
80417_PL_Tim Hague Sr lead

Perspectives

World Parkinson Congress 2019 Bloggers: Tim Hague

#WPC2019: We talk to Canadian blogger Tim Hague Sr

READ MORE
ballet

Health & Fitness

Scottish Ballet: dance therapy for Parkinson’s

Free weekly dance classes for Parkinson’s

READ MORE